| 名稱 | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat |
| 型號 | CBP74105 |
| 報價 |  |
| 特點 | ADCP Bioassay Effector Cell FcγRIa_NFAT/Jurkat,母細胞：Jurkat，凍存條件：90% FBS+10% DMSO |
產品搜索
相關文章
聯系我們
聯系人：蔣經理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區緯地路9號
Email： zhangxiangwen@cobioer.com
產品展示 / PRODUCTS
- 詳細內容
| CBP74105 | |
| I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. | |
| II. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIa_NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | N/A |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
| Storage: | Liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| III. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| IV.Representative Data | |
| |
Figure 1：Dose response of Rituximab in ADCP Bioassay Effector Cell FcγRIa/NFAT Reporter-Jurkat (C11)，the EC50 was 1.94ng/ml. | |
